Organogen

Our advanced biological therapeutics are produced and administered at the point-of-care. During the treatment, we harvest and concentrate autologous raw materials individually (Fibrin, Platelets, Stem Cells), that can be delivered separately or co-delivered with high precision, ensuring that the therapeutic agents are adhered and steadily released at the desired location. Our innovation arises from our unique capabilities to concentrate, combine and apply biological therapies in an efficient and scientifically proven method. The expertise that OrganoGEN has in the field of Regenerative Medicine in combination with Tissue Engineering and its strong partnerships can tailor-make complicated patient specific therapeutics depending on the type of surgery and treatment. Our team is made up of highly trained and experienced medical professionals, including our founder and CEO of the company Dr. Andreas Samourides. Andreas has a doctoral degree in Regenerative Medicine and Tissue Engineering, with experience in producing and co-applying autologous cell therapies as well as in developing biomimetic scaffolds for skin, oral mucosa, tendon and bone tissue engineering. The unique scientific, clinical and technical capabilities of OrganoGEN is the key for achieving the company's mission, to offer-> The best Regenerative Medicine technologies to medical providers -> Produce and control the therapeutic product following proper regenerative medicine practices to ensure that our patients receive the appropriate treatment -> Support the medical providers with patient specific treatment consultation and optimised regenerative medicine protocols -> Be ethical on the use and advertisement of the products and services we offer, to avoid misleading our clients and patients with overpromises and fake treatments -> Help the industry to grow by actively participating in R&D activities